^
Association details:
Biomarker:TP53 wild-type
Cancer:Small Lymphocytic Lymphoma
Regimen:FCR (cyclophosphamide + fludarabine IV + Rituxan (rituximab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:…CLL/SLL without del(17p)/TP53 mutation...Other recommended regimens...Reduced-dose FCR